Natalizumab: Treatment of IBD treatment of multiple sclerosis

Drugs of the Future

Volumn 25, Issue 9, 2000, Pages 917-921

  Sorbera, L A ^a   Martin, L ^a   Rabasseda, X ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; BETA1 INTEGRIN; CORTICOSTEROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GI 270384; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; ISIS 9125; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO; TR 14035; UNCLASSIFIED DRUG;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ULCERATIVE COLITIS; URTICARIA;

EID: 0033739275     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2000.025.09.593332     Document Type: Review

References (31)

1. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
2. 4 integrins in vivo
3. VLA-4-mediated signaling
4. Identification and characterization of the T lymphocyte adhesion receptor for an alternative ceil attachment domain (CS-1) in plasma fibronectin
5. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site
6. 1
7. Adhesion receptors of the immune system
8. 4 subunit inhibit the murine contact hypersensitivity response
9. 4 integrin monoclonal antibody
10. A monoclonal antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation in vivo
11. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways
12. Administration of monoclonal antibodies against vascular celt adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice
13. 1 integrin
14. 4 integrin suppresses and reverses active experimental allergic encephalomyelitis
15. Humanization of a mouse antibody against human α-4 integrin: A potential therapeutic for the treatment of multiple sclerosis
16. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
17. A placebo-controlled, pharmacodynamic, pharmacokinetic, tolerability and safety study of three doses of intravenous natalizumab in multiple sclerosis
18. 4 integrin antibody on brain lesion activity in MS
19. 4 integrin (Antegren(TM)) in active Crohn's disease
20. 4 integrin (Antegren(TM))
21. 4 integrin
22. 4 integrin (Antegren)
23. 4 integrin (Antegren) in active Crohn's disease
24. A placebo-controlled, safety, tolerability, dose escalation, PK study of various doses of intravenous Antegren in patients with multiple sclerosis (MS)
25. 4 integrin
26. 4 integrin
27. 4 integrin prevent leukocyte infiltration into the CNS and reverse progresion of experimental allergic encephalomyelitis